The J&J vaccine Phase 3 data shows it is 85% effective in preventing severe disease and 66% to 72% effective in preventing 'moderate to severe' COVID-19 infection. Johnson & Johnson in Talks With India for Clinical Study Of Single-Dose Covid-19 Vaccine
The J&J vaccine Phase 3 data shows it is 85% effective in preventing severe disease and 66% to 72% effective in preventing 'moderate to severe' COVID-19 infection. Johnson & Johnson in Talks With India for Clinical Study Of Single-Dose Covid-19 Vaccine
No comments:
Post a Comment